Literature DB >> 28523239

Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer.

Angel Qin1, Gregory P Kalemkerian1.   

Abstract

Entities:  

Year:  2016        PMID： 28523239      PMCID： PMC5433255          DOI： 10.21037/tcr.2016.11.22

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  8 in total

1.  Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.

Authors:  Young Hak Kim; Koichi Goto; Kiyotaka Yoh; Seiji Niho; Hironobu Ohmatsu; Kaoru Kubota; Nagahiro Saijo; Yutaka Nishiwaki
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

2.  Reinduction chemotherapy in small cell lung cancer.

Authors:  G Giaccone; P Ferrati; M Donadio; F Testore; A Calciati
Journal:  Eur J Cancer Clin Oncol       Date:  1987-11

3.  Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

Authors:  Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Steinar Aamdal
Journal:  Lung Cancer       Date:  2004-12-15       Impact factor: 5.705

4.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors:  Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

5.  Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.

Authors:  R M Huber; M Reck; H Gosse; J von Pawel; J Mezger; J G Saal; R Kleinschmidt; C Steppert; H Steppling
Journal:  Eur Respir J       Date:  2006-02-15       Impact factor: 16.671

6.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

7.  A phase II study of topotecan in patients with relapsed small-cell lung cancer.

Authors:  Koji Takeda; Shunichi Negoro; Toshiyuki Sawa; Kazuhiko Nakagawa; Masaaki Kawahara; Takeshi Isobe; Shinzoh Kudoh; Noriyuki Masuda; Hisanobu Niitani; Masahiro Fukuoka
Journal:  Clin Lung Cancer       Date:  2003-01       Impact factor: 4.785

8.  Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Authors:  Koichi Goto; Yuichiro Ohe; Taro Shibata; Takashi Seto; Toshiaki Takahashi; Kazuhiko Nakagawa; Hiroshi Tanaka; Koji Takeda; Makoto Nishio; Kiyoshi Mori; Miyako Satouchi; Toyoaki Hida; Naruo Yoshimura; Toshiyuki Kozuki; Fumio Imamura; Katsuyuki Kiura; Hiroaki Okamoto; Toshiyuki Sawa; Tomohide Tamura
Journal:  Lancet Oncol       Date:  2016-06-14       Impact factor: 41.316
  8 in total
  2 in total

Review 1.  Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2021-01-03       Impact factor: 3.396

2.  Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP).

Authors:  Andrés F Cardona; Leonardo Rojas; Zyanya Lucia Zatarain-Barrón; Alejandro Ruiz-Patiño; Luisa Ricaurte; Luis Corrales; Claudio Martín; Helano Freitas; Vladmir Cláudio Cordeiro de Lima; July Rodriguez; Jenny Avila; Melissa Bravo; Pilar Archila; Hernán Carranza; Carlos Vargas; Jorge Otero; Feliciano Barrón; Niki Karachaliou; Rafael Rosell; Oscar Arrieta
Journal:  Front Oncol       Date:  2019-04-17       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.